Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: vaccines - Panacea Biotec

Drug Profile

Research programme: vaccines - Panacea Biotec

Alternative Names: 13-Valent pneumococcal vaccine - Panacea Biotec; 15-Valent pneumococcal vaccine - Panacea Biotec; Dengue vaccine - Panacea Biotec; DTaP - Panacea Biotec; DTaP-HIB-TT-HepB-IPV - Panacea Biotec; DTaP-HIB-TT-IPV - Panacea Biotec; Hapy3; Hapyfive; Hapysix; Inactivated JEV vaccine - Panacea Biotec; Influenza virus vaccine universal - Panacea Biotec; Japanese encephalitis vaccine - Panacea Biotec; Live-attenuated dengue vaccine - Panacea Biotec; Measles vaccine - Panacea Biotec; Meninogococcal vaccine - Panacea Biotec; Neisseria meningitidis vaccine tetravalent - Panacea Biotec; Pneumococcal conjugate CRM vaccine; rDen-delta-30 NIH vaccine - Panacea Biotec; Recombinant influenza virus vaccine universal - Panacea Biotec; Recombinant tetravalent dengue vaccine - Panacea Biotec; Tetravalent meningococcal vaccine - Panacea Biotec; Universal influenza virus vaccine - Panacea Biotec

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacea Biotec; PT Bio Farma
  • Developer Panacea Biotec
  • Class Bacterial vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pneumococcal infections

Highest Development Phases

  • No development reported Dengue; Influenza virus infections; Japanese encephalitis; Measles; Meningococcal infections; Pneumococcal infections

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Japanese encephalitis in India (IM, Injection)
  • 23 Nov 2021 Preclinical trials in Japanese encephalitis ongoing in India (IM) (BioNet-Asia pipeline, November 2021)
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Dengue in India (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top